We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$53.5M
1-Year Est. Return
80.67%
This Fund
S&P 500
This Quarter
Est. Return
+25.68%
1 Year Est. Return
+80.67%
3 Year Est. Return
+80.2%
5 Year Est. Return
+49.87%
10 Year Est. Return
+446.13%
AUM
$746M
AUM Growth
+$200M
(+37%)
Cap. Flow
+$60.7M
Cap. Flow
% of AUM
8.13%
Top 10 Holdings %
Top 10 Hldgs %
76.52%
Holding
190
New
78
Increased
30
Reduced
20
Closed
61
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MON
Monsanto Co
MON
|
+$6.18M |
| 2 |
Verisk Analytics
VRSK
|
+$5.61M |
| 3 |
Air Products & Chemicals
APD
|
+$4.62M |
| 4 |
DNB
Dun & Bradstreet
DNB
|
+$4.57M |
| 5 |
Honeywell
HON
|
+$4.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FNB Corp
FNB
|
+$5.19M |
| 2 |
Dover
DOV
|
+$4.9M |
| 3 |
Associated Banc-Corp
ASB
|
+$3.9M |
| 4 |
KeyCorp
KEY
|
+$3.73M |
| 5 |
PACW
PacWest Bancorp
PACW
|
+$2.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.39% |
| 2 | Financials | 12.59% |
| 3 | Industrials | 5.43% |
| 4 | Materials | 3.1% |
| 5 | Technology | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Kirby Corp
KEX
$7.38B
| $707K | 0.09% |
10,582
-20,608
| -66% | -$1.4M |
|
102
Radian Group
RDN
$4.59B
| $694K | 0.09% |
+42,416
| New | +$726K |
|
103
Zimmer Biomet
ZBH
$18.7B
| $693K | 0.09% |
5,562
-5,444
| -49% | -$645K |
|
104
Moody's
MCO
$81.3B
| $661K | 0.09% |
+5,434
| New | +$636K |
|
105
HCA Healthcare
HCA
$91.8B
| $629K | 0.08% |
+7,209
| New | +$610K |
|
106
Herc Holdings
HRI
$4.68B
| $619K | 0.08% |
15,733
-44,621
| -74% | -$1.86M |
|
107
Manitowoc
MTW
$742M
| $601K | 0.08% |
24,986
-86,265
| -78% | -$2.02M |
|
108
Louisiana-Pacific
LPX
$4.56B
| $593K | 0.08% |
+24,607
| New | +$599K |
|
|
DERM
109
DELISTED
Dermira, Inc.
DERM
| $580K | 0.08% |
19,917
+1,737
| +10% | +$52.8K |
|
110
Morgan Stanley
MS
$318B
| $561K | 0.08% |
+12,579
| New | +$542K |
|
111
Heron Therapeutics
HRTX
$59.6M
| $513K | 0.07% |
+37,020
| New | +$536K |
|
112
Akebia Therapeutics
AKBA
$259M
| $504K | 0.07% |
+35,098
| New | +$445K |
|
113
CALL
Eastman Chemical
EMN
$7.6B
| $454K | 0.06% |
+1,500
| New | +$121K |
|
114
IES Holdings
IESC
$12.5B
| $437K | 0.06% |
+48,154
| New | +$416K |
|
|
BCPC
115
Balchem Corp
BCPC
$5.26B
| $432K | 0.06% |
5,557
-7,280
| -57% | -$580K |
|
|
GNMK
116
DELISTED
GenMark Diagnostics, Inc
GNMK
| $426K | 0.06% |
+36,046
| New | +$461K |
|
|
FRTA
117
DELISTED
Forterra, Inc
FRTA
| $348K | 0.05% |
+42,330
| New | +$552K |
|
118
PUT
Archer Daniels Midland
ADM
$41.8B
| $345K | 0.05% |
+2,000
| New | +$85.9K |
|
|
SIOX
119
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $334K | 0.04% |
+1,802
| New | +$316K |
|
120
Iovance Biotherapeutics
IOVA
$4.14B
| $318K | 0.04% |
+43,254
| New | +$275K |
|
|
BKI
121
DELISTED
Black Knight, Inc. Common Stock
BKI
| $302K | 0.04% |
+7,376
| New | +$292K |
|
122
CALL
Celanese
CE
$5.12B
| $280K | 0.04% |
+1,000
| New | +$89.1K |
|
|
PACW
123
DELISTED
PacWest Bancorp
PACW
| $280K | 0.04% |
6,000
-60,000
| -91% | -$2.93M |
|
124
Brown & Brown
BRO
$22.8B
| $273K | 0.04% |
+12,664
| New | +$271K |
|
|
DBVT
125
DBV Technologies
DBVT
$740M
| $257K | 0.03% |
+721
| New | +$246K |
|
Similar funds
OM
ICCON
HCM
ETCM
IDBONY
PCM
TCDRS
FPAM
Crestline Management's Q2 2017 Portfolio in Review
As of Q2 2017, Crestline Management held 190 positions worth $746M, up 37% from $546M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Crestline Management deployed $60.7M of net new capital in Q2 2017, opening 78 new positions and adding to 30 existing holdings. Its largest new stake was Monsanto Co: 53,000 shares worth $6.27M.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 75% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was FNB Corp, an estimated $5.19M trimmed.
- Crestline Management's largest Q2 2017 buy was Monsanto Co: 53,000 shares worth $6.27M.
- Crestline Management added most to Honeywell in Q2 2017, an estimated $4.05M increase.
- Crestline Management's biggest Q2 2017 reduction was FNB Corp, cutting an estimated $5.19M.
- Crestline Management fully exited Dover in Q2 2017, selling an estimated $4.9M.
- Crestline Management's ten largest holdings make up 77% of its $746M portfolio in Q2 2017.
- Crestline Management opened 78 new positions and closed 61 in Q2 2017.
- Crestline Management's portfolio value rose 37% quarter-over-quarter to $746M.
Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.